ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"

By Insights from 2023 ASH Annual Meeting FEATURING Marlise R. Luskin

0 views

December 29, 2023

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale

22:37

Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

14:39

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Immunotherapies in Acute Leukemias: 2024 Update

Feat. C. Lai

09:42

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Post-Transplant Cyclophosphamide-Based Gv…

Feat. M. Al Malki

16:28

Fred Hutchinson Cancer Center

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Feat. R. Cassaday

13:26

Steven Pavletic

Chronic GvHD: Main Complications After ASCT

28:33

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale

31:41

MyCancerHaven

Treating Adults With Newly Diagnosed ALL

Feat. R. Vij, A. Patel

28:07

Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock

01:29

Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

22:30

Rush University Medical Center

Selection and Sequencing of Chronic GVHD Therapy

Feat. S. Kosuri

17:51

Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry

04:11

Total Health

ASCO 2022 Updates in Leukemia and MDS

Feat. D. Sallman

11:02

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Asciminib Combined With Dasatinib and Predn…

Feat. M. Luskin

37:03

SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: ALL

Feat. E. Jabbour

27:47

City of Hope

Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…

Feat. I. Amanam

20:38

Ernst Holler

GVHD: Importance of Early Detection and Management

44:21

Tisch Cancer Institute at Mount Sinai

Early T-Cell Precursor ALL Case Discussion: Diagnosis, Prognosis, an…

Feat. A. Siegel

12:09

Pooja Khandelwal

Login

Login

Join VuMedi

ASH 2023 Insights: "Mini-Hyper-CVD Plus Venetoclax for Older Adults With ND Ph- B-ALL or T-ALL"

Recommended